Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M18,658Revenue $M512Net Margin (%)-5.7Altman Z-Score10.8
Enterprise Value $M18,770EPS $-0.3Operating Margin %1.9Piotroski F-Score4
P/E(ttm)--Beneish M-Score-2.2Pre-tax Margin (%)-5.6Higher ROA y-yY
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio3.1Cash flow > EarningsY
Price/Sales32.05-y EBITDA Growth Rate %--Current Ratio3.1Lower Leverage y-yY
Price/Free Cash Flow812y-y EBITDA Growth Rate %--ROA % (ttm)-4.3Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M179ROIC % (ttm)48.7Gross Margin Increase y-yN

Gurus Latest Trades with INCY

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
INCYMariko Gordon 2014-12-31 Sold Out -0.05%$45.6 - $78.89
($65.73)
$ 105.5861%Sold Out0
INCYKen Fisher 2014-12-31 Add$45.6 - $78.89
($65.29)
$ 105.5862%Add 97.08%14,870
INCYVanguard Health Care Fund 2014-09-30 Add0.07%$45.35 - $56.59
($50.13)
$ 105.58111%Add 6.08%10,174,343
INCYMariko Gordon 2014-09-30 Add$45.35 - $56.59
($50.13)
$ 105.58111%Add 6.55%25,283
INCYKen Fisher 2014-09-30 Reduce$45.35 - $55.78
($50.07)
$ 105.58111%Reduce 38.28%7,545
INCYVanguard Health Care Fund 2014-06-30 Add0.68%$43.1 - $56.39
($50.98)
$ 105.58107%Add 95.66%9,591,143
INCYMariko Gordon 2014-06-30 Reduce-0.19%$43.1 - $56.39
($50.98)
$ 105.58107%Reduce 78.93%23,728
INCYGeorge Soros 2014-06-30 Sold Out -0.01%$43.1 - $56.39
($50.98)
$ 105.58107%Sold Out0
INCYKen Fisher 2014-06-30 Buy $43.1 - $56.39
($50.98)
$ 105.58107%New holding12,225
INCYVanguard Health Care Fund 2014-03-31 Add0.07%$49.94 - $68.83
($62.06)
$ 105.5870%Add 9.97%4,901,968
INCYMariko Gordon 2014-03-31 Reduce-0.03%$49.94 - $68.83
($62.06)
$ 105.5870%Reduce 12.67%112,623
INCYGeorge Soros 2014-03-31 Buy 0.01%$49.94 - $68.83
($61.83)
$ 105.5871%New holding23,200
INCYVanguard Health Care Fund 2013-12-31 Add0.1%$34.71 - $51.34
($43.56)
$ 105.58142%Add 17.08%4,457,643
INCYMariko Gordon 2013-12-31 Reduce-0.06%$34.71 - $51.34
($43.45)
$ 105.58143%Reduce 20.50%128,959
INCYVanguard Health Care Fund 2013-06-30 Add0.05%$19.07 - $24.49
($21.85)
$ 105.58383%Add 21.52%3,807,443
INCYVanguard Health Care Fund 2013-03-31 Buy 0.29%$16.61 - $24.95
($20.44)
$ 105.58417%New holding3,133,100
INCYGeorge Soros 2011-03-31 Sold Out $13.37 - $16.56
($14.71)
$ 105.58618%Sold Out0
INCYGeorge Soros 2010-12-31 Buy $14.51 - $17.17
($16.13)
$ 105.58555%New holding15,000
INCYBill Gates 2009-06-30 Sold Out -0.01%$2.06 - $3.84
($2.79)
$ 105.583684%Sold Out0
INCYFirst Eagle Investment 2009-03-31 Sold Out $2.14 - $3.78
($2.9)
$ 105.583541%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

INCY is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


INCY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Daly James MEVP, Chief Commercial Officer 2015-06-23Sell11,691$108.24-2.46view
Levy Richard SEVP, Chief Drug Dev Officer 2015-06-19Sell20,000$108.13-2.36view
Siegel Eric H.EVP, General Counsel 2015-06-12Sell2,223$105.310.26view
Levy Richard SEVP, Chief Drug Dev Officer 2015-06-08Sell3,937$107.58-1.86view
FRIEDMAN PAUL ADirector 2015-05-27Sell196,751$107.23-1.54view
Daly James MEVP, Chief Commercial Officer 2015-05-26Sell12,093$106.4-0.77view
FRIEDMAN PAUL ADirector 2015-05-22Sell102,243$108.22-2.44view
Siegel Eric H.EVP, General Counsel 2015-05-14Sell2,222$104.990.56view
Levy Richard SEVP, Chief Drug Dev Officer 2015-05-06Sell7,412$99.436.19view
Daly James MEVP, Chief Commercial Officer 2015-04-23Sell36,941$107.67-1.94view

Quarterly/Annual Reports about INCY:

News about INCY:

Articles On GuruFocus.com
Weekly CFO Sells Highlight: Aramark, Incyte Corp Ltd., Facebook Inc. Jun 09 2014 
Weekly Insider Sells Highlight: ARMK, INCY, ESC, HUN Jun 08 2014 
Weekly Insider Sells Highlight: CPN, INCY, GPK, CODE Feb 23 2014 
Weekly CFO Sells Highlight: Pandora Media Inc, Incyte Corp Ltd, Google Inc, American Airlines Group Feb 24 2014 
Weekly CEO Sells Highlight: ExOne Co, Atmel Corporation, Best Buy and Incyte Corp Ltd. Sep 22 2013 
Weekly CFO Sells Highlight: INTU, INCY, RLD, MIDD, XONE Sep 15 2013 
Weekly CEO Sells Highlight: DIS, LMT, INCY, ADBE May 14 2012 
Weekly Top Insider Buys: VTR, INCY, FULT, HMA, CMC Jan 23 2012 
04 stocks with insider buying of more than $1.5 million since beginning of 2012 Jan 22 2012 
Weekly CFO Sales Highlight: EPIQ, INCY, AVB, JOSB, PCS, FLO Jun 12 2011 

More From Other Websites
Immunovaccine Collaborates With Incyte to Evaluate Novel Immunotherapy Combination for Patients With... Jun 25 2015
Charting a sluggish, but bullish, summer trend Jun 23 2015
INCYTE CORP Files SEC form 8-K, Change in Directors or Principal Officers Jun 19 2015
Incyte Announces Organizational and Management Changes to Drive Future Global Expansion Jun 19 2015
Incyte Announces Organizational and Management Changes to Drive Future Global Expansion Jun 19 2015
GEVA helped advance Sectoral Asset 9.4% in May. ALXN did not Jun 17 2015
S&P 500 holds major support, preserving the bull trend Jun 16 2015
JMP Sees A 'Negative Market Tone' In Biotechnology Jun 15 2015
Lilly and Incyte unveil detailed data on two pivotal studies of baricitinib in rheumatoid arthritis Jun 10 2015
Lilly and Incyte unveil detailed data on two pivotal studies of baricitinib in rheumatoid arthritis Jun 10 2015
Lilly and Incyte unveil detailed data on two pivotal studies of baricitinib in rheumatoid arthritis Jun 10 2015
The S&P 500 has reached a critical technical test Jun 09 2015
Advaxis Announces FDA Clearance of Investigational New Drug Application for Phase 2 Study of... Jun 01 2015
ASCO '15: CTI Biopharma Takes on Myelofibrosis Drug Rival May 30 2015
These biotechs may surge on drug news: Expert May 29 2015
What to expect from ASCO May 29 2015
Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase III Data May 28 2015
Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase III Data May 28 2015
Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase III Data May 28 2015
Earnings Estimates Moving Higher for Incyte (INCY): Time to Buy? - Tale of the Tape May 27 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK